The Thirona LungQ software provides reproducible CT values for pulmonary tissue which is essential for providing quantitative support for diagnosis and follow up examination. The LungQ software can be used to support physician in the diagnosis and documentation of pulmonary tissues images (e.g. abnormalities) from CT thoracic datasets. Three-D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation, and reporting tools are provided.
Clinical role
Provides Three-D segmentation and isolation of sub-compartments, volumetric analysis, density and fissure evaluations, and reporting tools, giving reproducible CT values as quantitative support for physician diagnosis, documentation, and follow-up of thoracic CT.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Stand-alone command-line software that must be run from a command-line interpreter and does not have a graphical user interface.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyCT/CTA · Chest/Lung
Workflow roleProvides Three-D segmentation and isolation of sub-compartments, volumetric analysis, density and fissure evaluations, and reporting tools, giving reproducible CT values as quantitative support for physician diagnosis, documentation, and follow-up of thoracic CT.
Required inputCT thoracic datasets: Computed Tomography (CT) scans of the thorax that may contain pulmonary abnormalities.
Output and human actionThree-D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation, and reporting tools are provided.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The Thirona LungQ software provides reproducible CT values for pulmonary tissue which is essential for providing quantitative support for diagnosis and follow up examination. The LungQ software can be used to support physician in the diagnosis and documentation of pulmonary tissues images (e.g. abnormalities) from CT thoracic datasets. Three-D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation, and reporting tools are provided.
Provides Three-D segmentation and isolation of sub-compartments, volumetric analysis, density and fissure evaluations, and reporting tools, giving reproducible CT values as quantitative support for physician diagnosis, documentation, and follow-up of thoracic CT.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The Thirona LungQ software provides reproducible CT values for pulmonary tissue which is essential for providing quantitative support for diagnosis and follow up examination." … "The LungQ software can be used to support physician in the diagnosis and documentation of pulmonary tissues images (e.g., abnormalities) from CT thoracic datasets.". Read from the exact FDA decision document on 2026-11-14.
CT thoracic datasets: Computed Tomography (CT) scans of the thorax that may contain pulmonary abnormalities.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The LungQ software is designed to aid in the interpretation of Computed Tomography (CT) scans of the thorax that may contain pulmonary abnormalities." … "The LungQ software can be used to support physician in the diagnosis and documentation of pulmonary tissues images (e.g., abnormalities) from CT thoracic datasets.". Read from the exact FDA decision document on 2026-11-14.
Three-D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation, and reporting tools are provided.
Exact FDA submission
Checked 2026-09-01
Clinical output reported in the exact-submission ACR model card.
Stand-alone command-line software that must be run from a command-line interpreter and does not have a graphical user interface.
Exact FDA submission
Checked 2026-11-14
Packet wording: "LungQ is stand-alone command-line software which must be run from a command-line interpreter and does not have a graphical user interface.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Study type: Stand-Alone Performance
Public source
Exact FDA submission
Checked 2026-09-01
Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
LungQ v3.0.0 regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K232412
IndependenceIndependence not established
K232412
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232412. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT thoracic datasets: Computed Tomography (CT) scans of the thorax that may contain pulmonary abnormalities.
Scope: Exact FDA submission. Packet wording: "The LungQ software is designed to aid in the interpretation of Computed Tomography (CT) scans of the thorax that may contain pulmonary abnormalities." … "The LungQ software can be used to support physician in the diagnosis and documentation of pulmonary tissues images (e.g., abnormalities) from CT thoracic datasets.". Read from the exact FDA decision document on 2026-11-14.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes DICOM data loading for LungQ v3.0.0 and a restricted interface with a third-party end-user interface that uses standard input and output formats. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Data Loading DICOM Same Same Application Command-line interface Same Equivalent" … "The restricted interface of LungQ with the third party end-user-interface is well controlled by the use of standard input and output formats.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Three-D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation, and reporting tools are provided.
Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Three-D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation, and reporting tools are provided.
Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes DICOM data loading for LungQ v3.0.0 and a restricted interface with a third-party end-user interface that uses standard input and output formats. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Data Loading DICOM Same Same Application Command-line interface Same Equivalent" … "The restricted interface of LungQ with the third party end-user-interface is well controlled by the use of standard input and output formats.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Thirona's quality and compliance page states its product development is grounded in a certified quality management system (ISO 13485) and lists ISO 27001 and EU GDPR under its information security and data governance standards, applied to its lung image analysis software.
Vendor-wide
Checked 2026-10-27
Vendor statement; the certificate was not read. Page is company-scoped for Thirona's lung image analysis software including LungQ. Exact-release scope is not established. Applied only to Thirona BV entries; 'Thirona Corporation' (K173821) is an unbridged entity variant.
ACR AI Central provides an exact-submission model card for LungQ v3.0.0; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-08Last searched
21Fields reviewed
9Source classes checked
6Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR and official vendor material provide bounded catalog or product-family context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 6 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state a care setting or patient population for the subject device. Confirm intended sites and patients with the vendor and local policy.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K232412 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.